at://
/
app.bsky.feed.post
/
3mmpmdcyync2r
sign in
All
4
Record
2
Post
1
PostEmbed
1
Post
by @danabra.mov
PostEmbed
by @danabra.mov
Record
by @jimpick.com
Record
by @atsui.org
+ new component
Post
New data from Noxopharm (ASX:NOX) shows its Sofra™ platform can amplify TLR8 immune response 200-fold, unlocking potent new cancer immunotherapy potential in a $185B market by 2035. bit.ly/3Pl6Gvy #biotech #ImmunoOncology
18d
bit.ly
